Performance of the T2Candida Panel for the diagnosis of intra-abdominal candidiasis

Lamoth F\textsuperscript{1,2†}, Clancy CJ\textsuperscript{3†}, Tissot F\textsuperscript{1}, Squires K\textsuperscript{3}, Eggimann P\textsuperscript{4}, Flückiger U\textsuperscript{5}, Siegemund M\textsuperscript{6}, Orasch C\textsuperscript{7}, Zimmerli S\textsuperscript{8}, Calandra T\textsuperscript{1}, Marchetti O\textsuperscript{1,9}, Nguyen MH\textsuperscript{3††}, Bochud PY\textsuperscript{1††}, on behalf of the Fungal Infection Network of Switzerland (FUNGINOS)

† These authors (FL, CJC) equally contributed to the work.

†† These authors (MHN, PYB) equally contributed to the work.

1 Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

2 Institute of Microbiology, Department of Laboratories, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

3 Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

4 Service of Orthopedics and Traumatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

5 Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital of Basel, Basel, Switzerland

6 Intensive Care Unit, University Hospital of Basel, Basel, Switzerland

7 Hirslanden Klinik St. Anna, Luzern, Switzerland

8 Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland

9 Hôpital de Morges, Ensemble Hospitalier de La Côte, Morges, Switzerland

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
* Corresponding author:

Frederic Lamoth
Centre Hospitalier Universitaire Vaudois
Rue du Bugnon 46
1011 Lausanne / Switzerland
Phone: +41 31 410 1010
Email: Frederic.Lamoth@chuv.ch

Authors’ contributions:

FL: study design, data analyses, writing of manuscript
CJC: study design, data analyses, writing of manuscript
FT: study design, patients’ recruitment, review and editing of manuscript
KS: T2Candida testing
EP: study design, patients’ recruitment, review and editing of manuscript
SM: patients’ recruitment, review and editing of manuscript
OC: patients’ recruitment, review and editing of manuscript
SZ: study design, review and editing of manuscript
TC: study design, review and editing of manuscript
OM: study design, review and editing of manuscript
MHN: study design, data analyses, writing of manuscript
PYB: study design, data analyses, writing of manuscript.
ABSTRACT

Performance of T2 Candida for detecting intra-abdominal candidiasis (IAC) was assessed in 48 high-risk patients. T2 Candida sensitivity/specificity and positive/negative predictive values were 33%/93% and 71%/74%, respectively. IAC was present in 100% cases with concordant positive T2 Candida/1,3-beta-d-glucan and absent in 90% of concordant negative results. Combination T2 Candida/1,3-beta-d-glucan may help guiding treatment decisions.

Keywords: invasive candidiasis, candidemia, T2 magnetic resonance, blood cultures, beta-glucan
INTRODUCTION

Candida spp. frequently cause sepsis and invasive infections in intensive care unit (ICU) patients [1]. Intra-abdominal candidiasis (IAC), manifesting most often as peritonitis and/or abscesses, is common among ICU patients who have undergone complicated abdominal surgery or with other gastrointestinal (GI) tract disorders. Blood cultures represent the diagnostic gold standard for invasive candidiasis, but remain sterile in >80% of patients with IAC [2, 3]. Cultures of intra-abdominal samples generally are required to diagnose IAC, but they are limited by low sensitivity, slow turn-around and need for invasive procedures. Reliance upon cultures may delay antifungal treatment of IAC, which can contribute to high mortality rates [2, 3]. Current non-culture diagnostic methods, such as detection of 1,3-beta-d-glucan (BDG) in serum, identify some patients with IAC who are missed by cultures. However, serum BDG assays are limited by lack of specificity and high false-positivity [4, 5]. The development and validation of rapid diagnostic tests for IAC and other invasive candidiasis is a pressing priority.

The T2Candida panel (T2C; T2 Biosystems, Lexington, MA) is a fully automated magnetic resonance-based molecular test for direct detection of the five major pathogenic Candida spp. (C. albicans/C. tropicalis, C. glabrata/C. krusei, and C. parapsilosis) in whole blood samples within 5 hours [6]. T2C was cleared by the Food and Drug Administration (FDA) and received the “Conformité Européenne” (CE) certification for diagnosis of candidemia, based largely on clinical trial data demonstrating sensitivity and specificity of ~90% and ~98%, respectively, for detecting target Candida spp. [7, 8]. Data on T2C performance for diagnosis of non-candidemic invasive candidiasis, such as IAC, are scant [9]. Our objective was to assess the performance of T2C for detection of IAC compared to blood cultures and BDG testing.
METHODS

Cases were included from a previous prospective cohort study by the Fungal Infection Network of Switzerland (FUNGINOS) [5]. Adults (≥18 years old) in ICUs of two university hospitals were enrolled consecutively if they exhibited the following risk factors for IAC: i) recurrent GI tract perforation (anastomotic leakage or recurrent surgical transection of the gut), ii) acute necrotizing pancreatitis (Balthazar grade D-E) or iii) recent abdominal surgery (<3 days) and Candida colonization of non-sterile sites (e.g., mouth, urine, stool, skin or respiratory tract). A diagnosis of IAC was established if a Candida spp. was isolated by peri-operative intra-abdominal culture, as previously described [5]. Blood cultures (two sets of BACTEC Plus aerobic/F and Lytic anaerobic/F bottles, Becton Dickinson, Sparks, MD) were performed in cases of fever or clinical suspicion of infection. Blood and serum samples were collected twice weekly from inclusion until two weeks after ICU discharge. Sera underwent BDG testing (Fungitell™, Associates of Cape Cod, Falmouth, MA; positivity cut-off ≥80 pg/ml) as part of the previous study [5]. T2C testing was performed on archived frozen blood samples that were thawed, and in which sufficient volume was available (≥3 ml). Samples collected within 72 hours of IAC diagnosis, or between days 7-10 from study inclusion for patients without IAC, were analyzed. Performance of T2C for the diagnosis of IAC was compared to that of BDG and blood cultures.

This study was approved by the local ethics committee and written informed consent was obtained from patients or their legal representatives [5].

RESULTS

Valid T2C results were obtained for 48 ICU patients who were at-risk for IAC, including 18 patients with IAC and 30 patients who did not fulfill IAC criteria as defined above. Clinical characteristics of patients are presented in Supplementary Material (Table S1).
C. albicans was the causative agent of IAC in 72% (13/18) of patients. C. tropicalis (n=2), Candida spp. not included in the T2C panel (C. kefyr, C. lusitaniae), and C. albicans/C. glabrata (n=1) were involved in the remaining cases. Eleven percent (2/18) of patients with IAC were diagnosed with candidemia by blood culture. T2C was positive in 33% (6/18) of IAC patients, including the two patients with candidemia. Candida spp. detected by T2C matched those from intra-abdominal cultures. Eleven percent (2/18) of patients were receiving antifungal treatment for 4 days at time of IAC diagnosis; T2C was negative in these patients. T2C was negative in 93% (28/30) of patients without IAC. The two patients in whom T2C was positive had negative BDG results in follow-up samples despite Candida colonization at multiple sites, did not receive antifungal therapy, and survived until hospital discharge.

Per-patient sensitivity, specificity, positive and negative predictive values (PPV and NPV), and positive and negative likelihood ratios for T2C and BDG are provided in Table 1. Concordant positive T2C/BDG results were associated with IAC in 100% (5/5) of patients. Concordant negative results were associated with absence of IAC in 90% (18/20) of patients. Discordant T2C and BDG results were observed in 48% (23/48) of patients, 48% (11/23) of whom had IAC.

DISCUSSION
To our knowledge, this is the first study to determine T2C performance specifically for the diagnosis of IAC. T2C sensitivity and specificity were 33% and 93%, respectively. Our findings are in keeping with those reported recently in a study from two ICUs in Denmark, in which T2C sensitivity and specificity for proven or likely deep-seated invasive candidiasis (including a limited number of IAC, n=6) were 45% and 96%, respectively [9]. Similar to the Danish study, our analysis demonstrated the ability of T2C to detect non-candidemic deep-seated invasive candidiasis.
The performance of T2C in diagnosing IAC, marked by high specificity and PPV, stands in contrast to that reported previously for serum BDG. In previous studies, BDG sensitivity and specificity for IAC ranged from 53%-77% and 55%-78%, respectively [5, 10-12]. The relative strengths of BDG for diagnosing IAC compared to T2C are improved sensitivity and excellent NPV. The complementary performance characteristics of T2C and BDG suggest that the tests might have greatest clinical utility if used in combination. Indeed, concordant positive T2C and BDG results indicated IAC in 100% cases and concordant negative results could reliably exclude IAC in 90% cases. The probability of IAC if one test was positive and the other was negative was 48%, which is likely sufficient to justify antifungal therapy in at-risk patients with signs of intra-abdominal infection in whom an alternative diagnosis is not apparent. For these patients, the need for ongoing antifungal therapy should be reassessed based on clinical evolution and microbiological results.

This study was limited by its small size and retrospective design. Use of freeze-thaw archived samples may account for the high rate of invalid T2C results (31%), which exceeded 7.6% and 9.2% rates for freshly-collected and freeze-thaw samples, respectively, in clinical trials [7, 8]. A potential explanation for these findings is that the frozen samples were stored for several years, following their original collection during the FUNGINOS study. Indeed, even for samples giving putatively “valid” negative results, it is possible that test performance was impacted. The influence of antifungal therapy on T2C performance for diagnosing IAC remains unclear. While only 11% of our patients were receiving an antifungal drug at time of T2C testing, the corresponding figure was 77% among subjects in the Danish ICU study [9]. The low yield of blood cultures for IAC detection in the present study is comparable to that previously reported [2, 3]. Only standard blood cultures (aerobic and anaerobic vials) were used. It is unclear if the use of specific fungal culture vials increases the performance of blood culture for detection of candidemia [13].
T2C may have generated false-positive results in two patients who did not have clinical evidence of invasive candidiasis and in whom outcomes were favorable in the absence of antifungal therapy. However, we cannot exclude that T2C may have detected transient candidemia in these patients that was not diagnosed by blood cultures. Finally, in our study, 11% (2/18) of IAC was attributed to *Candida* species not included in the T2C panel. The fact that the spectrum of detection of T2C is restricted to five *Candida* species is an intrinsic limitation of the test. These five species account for ≥95% of invasive candidiasis at most centers, but local epidemiology must be taken into account in determining the value of the panel at each hospital [7]. At present, T2C does not detect emerging *Candida auris*, which has been involved in nosocomial outbreaks. A research prototype T2C assay including this species has sensitivity and specificity comparable to that reported for the current panel [14].

In conclusion, T2C may detect at least some cases of non-candidemic IAC. Moreover, combination T2C/BDG testing may be useful in defining the probability of IAC as high (approaching 100%), moderate (~50%), or low (≤10%) based on concordant positive, discordant, and concordant negative results, respectively. Follow-up investigations of T2C in diagnosing IAC and other types of invasive candidiasis using freshly collected samples are needed, as are studies of the impact of T2C- and BDG-guided treatment on patient outcomes, antifungal stewardship, and hospital costs.
FUNDING

This work was supported by a grant from the Fungal Infection Network of Switzerland (FUNGINOS).

Other funding sources for this study include:
Associates of Cape Cod, U.S.A.: discounted Fungitell lab kits.
Biomérieux France: unrestricted grant support.
European Community’s Seventh Framework program (FP7-2007-2013) under grant agreement n_HEALTH-F2-2010-26033-ALLFUN.
Foundation for the Advancement in Medical Microbiology and Infectious Diseases (FAMMID), Lausanne, Switzerland: unrestricted grant support.

CONFLICT OF INTERESTS DISCLOSURE

Dr. Lamoth served on advisory boards for Merck, Gilead and Basilea. Dr Bochud served on advisory boards for Pfizer. Dr. Clancy has been awarded investigator-initiated research grants from T2 Biosystems, Astellas, Merck, Melinta, and Cidara for projects unrelated to this project, served on advisory boards or consulted for Astellas, Merck, the Medicines Company, Cidara, Scynexis, Shionogi, Opex and Needham & Company, and spoken at symposia sponsored by T2Biosystems and Merck. Dr. Nguyen has been awarded investigator-initiated research grants from T2 Biosystems, Astellas, Merck, Melinta and Cidara for projects unrelated to this study, and served on advisory boards for Astellas, Merck, Scynexis and Shionogi.

Dr Bochud is recipient of grants from the Swiss National Science Foundation (SNSF 324730_165954 and 33IC30_179636), as well as from the Leenaards and the Santos Suarez foundations. Dr. Lamoth is recipient of grants from the Swiss National Science Foundation (PZ00P3_161140) and the Santos Suarez Foundation.
The FUNGINOS Foundation received unrestricted grant support from EssexSchering-Plough Switzerland; Gilead Switzerland; Merck, Sharp and Dohme-Chibret Switzerland; Novartis Switzerland; and Pfizer Switzerland.

ACKNOWLEDGMENTS

The authors and the FUNGINOS Group thank Mrs. Corine Guyaz, Mrs. Monika Ochsner, Mr. Chris Pluess, and Dr. Chloé’ Kaech for outstanding assistance in collecting clinical data and blood samples. They also thank Dr. Agnieszka Wojtowicz, Mrs. Sophie Chevalley, Mr. Christian Durussel, Mr. Johnatan Hamilton, and Mr. Benoit Pesse for outstanding technical support in processing blood samples and performing laboratory analyses.
REFERENCES

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9.

2. Bassetti M, Righi E, Ansaldi F, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 2015; 41:1601-10.

3. Vergidis P, Clancy CJ, Shields RK, et al. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS One 2016; 11:e0153247.

4. Clancy CJ, Nguyen MH. Diagnosing Invasive Candidiasis. J Clin Microbiol 2018; 56.

5. Tissot F, Lamoth F, Hauser PM, et al. beta-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 2013; 188:1100-9.

6. Pfaller MA, Wolk DM, Lowery TJ. T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. Future Microbiol 2016; 11:103-17.

7. Clancy CJ, Pappas PG, Vazquez J, et al. Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clin Infect Dis 2018; 66:1678-86.

8. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60:892-9.

9. Arendrup MC, Andersen JS, Holten MK, et al. Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis. Open Forum Infect Dis 2019; 6:ofz136.

10. Leon C, Ruiz-Santana S, Saavedra P, et al. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care 2016; 20:149.
11. Leon C, Ruiz-Santana S, Saavedra P, et al. Value of beta-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 2012; 38:1315-25.

12. Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, beta-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis 2012; 54:1240-8.

13. Kirby JE, Delaney M, Qian Q, Gold HS. Optimal use of Myco/F lytic and standard BACTEC blood culture bottles for detection of yeast and mycobacteria. Arch Pathol Lab Med 2009; 133:93-6.

14. Sexton DJ, Bentz ML, Welsh RM, Litvintseva AP. Evaluation of a new T2 Magnetic Resonance assay for rapid detection of emergent fungal pathogen Candida auris on clinical skin swab samples. Mycoses 2018; 61:786-90.
Table 1. Performance of T2Candida and 1,3-beta-d-glucan for detection of intra-abdominal candidiasis

|                  | T2Candida           | 1,3-beta-d-glucan |
|------------------|---------------------|-------------------|
| Sensitivity      | 33.3% (13.3 – 59.0) | 83.3% (58.6 – 96.4) |
| Specificity      | 93.3% (77.9 – 99.2) | 66.7% (47.2 – 82.7) |
| Positive predictive value * | 71.1% (35.7 – 91.6) | 55.2% (41.6 – 68.0) |
| Negative predictive value * | 74.0% (66.9 – 80.0) | 89.0% (73.7 – 95.9) |
| Positive likelihood ratio | 5.00 (1.13 – 22.18) | 2.50 (1.45 – 4.32) |
| Negative likelihood ratio | 0.71 (0.51 – 1.00) | 0.25 (0.09 – 0.72) |

* Calculated for a disease prevalence of 33% in the original prospective cohort study [5].

Values in brackets are 95% confidence intervals.